东方医药网导读:据11 月 18 日消息,CytRx Corp 宣布由于一位受试者死亡,美国食品药品监督管理局(FDA)下令该公司试验性抗癌药物——aldoxorubicin 临床试验暂停招募新受试者,这一消息使得 CytRx 股价在早盘交易中下降了 11 个百分点。而本周一 CytRx 在 Nasdaq 的收盘价为 2.76 美元。 死亡的患者是通过 CytRx...
text editorEmerging Infectious Diseases
CytRx Enforcement. If NantCell elects not to enforce any patent within the Licensed Patents, then it shall so notify CytRx in writing within ninety (90) days of receiving notice that an Infringement e...
Welcome to the CytRx Corporation Securities Litigation Settlement Website This website has been established to provide general information regarding the proposed Settlement of the consolidated action entitled In re CytRx Corporation ("CytRx") Securities Litigation, No. 2:14-CV-01956-GHK-PJW, pending...
新闻稿:CytRx公司强调其许可药物aldoxorubiin的重大积极事件 CytRx Corporation Highlights Significant Positive Events From its Licensed Drug Aldoxorubicin CytRx公司重点介绍其获得许可的药物--醛多柔比星的重大积极事件 CytRx Licensee ImmunityBio, Previously NantCell, Inc., Announced Complete Response in Metastat...
Clinical researchPhase IIIEvents MORE ON THIS TOPIC Vaccines FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount March 5, 2025 · 2 min read · Tristan Manalac Cancer BeiGene Gets Yet Another Label Expansion f...
CytRx宣布启动aldoxorubicin在二线软组织肉瘤患者中的Ph3期临床试验,将在2016年第四季度对数据进行分析由于招募患者工作时在2014年11月出现了一项特殊的临床事件而中断据查为一例患者死亡在中断得到解决恢复招募工作后入组的患者其中近三分之二的患者未有充分的进行随访工作 CytRxAnnounces Initial Results of Phase 3 ...
Chicago, IL - November 12, 2018 - Stocks in this week's article areRalph Lauren Corp.(RL),The Estee Lauder Companies Inc.EL,GMS Inc.GMS,CytRx Corp.CYTRandT2 Biosystems Inc.TTOO. Bet on Rising P/E Investing with These 5 Top-Ranked Stocks ...
Trade-Ideas LLC identified CytRx (CYTR) as a strong on high relative volume candidate CYTR Latest Stock Market News & Data Jul 13, 2016 10:08 AM EDT Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock Trade-Ideas LLC identified CytRx (CYTR) as a weak on high...
CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 As A Treatment For Advanced Pancreatic CancerCytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 As A Treatment For Advanced Pancreatic CancerCytRx Corporation...